张婧,杨宝春,张复春,邹尚荣
ZHANG Jing,YANG Baochun,ZHANG Fuchun,ZOU Shangrong

• 1:广州市第八人民医院药剂科
• 2:广州第八人民医院感染科

摘要(Abstract)：

目的探讨IL-11对登革热患者血小板减少的作用,为该药的临床应用提供依据。方法采用回顾性分析,将登革热伴血小板减少者分为对照组及治疗组(IL-11 2 mg ih),考察2组5 d内的PLT水平及住院天数。结果与对照组相比,治疗组IL-11给药第5天可显著升高PLT水平,差异有统计学意义(P<0.05),且该疗效差异在男性患者中更明显。但2组在血小板减少持续时间以及住院天数方面,差异无统计学意义(P>0.05)。结论 IL-11可在一定程度上促进登革热伴血小板减少者血小板的生成,提高病程后期的PLT峰值。
OBJECTIVE To investigate the effect of IL-11 on Dengue fever with thrombocytopenia,and provide data for clinical application. METHODS A retrospective analysis was employed. Patients of Dengue fever with thrombocytopenia were divided into control group and treatment group( IL-11 2 mg ih). The PLT levels for 5 d and hospitalization time of 2 groups were investigated.RESULTS Compared with control group,the PLT level of patients in the treatment group was significantly higher on the fifth day after IL-11 administration( P<0.05). Moreover,the curative effects were more obvious in males. However,there were no statistically significant differences in the duration of thrombocytopenia and hospital stays between 2 groups( P > 0. 05). CONCLUSION For thrombocytopenia accompanying Dengue fever,IL-11 may promote the generation of PLT to some extent,and improve the peak level in the late course of the disease.

关键词(KeyWords)： IL-11;登革热;血小板减少
IL-11;Dengue fever;thrombocytopenia

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张婧,杨宝春,张复春,邹尚荣
ZHANG Jing,YANG Baochun,ZHANG Fuchun,ZOU Shangrong

参考文献(References)：

• [1]登革热诊疗指南(2014年第2版).传染病信息,2014,(05):262-265.
• [2]Suliman MI,Qayum I,Saeed F.Randomized clinical trial of human interleukin-11 in Dengue fever-associated thrombocytopenia[J].J Coll Physicians Surg Pak,2014,24(3):164-168.
• [3]Guzman MG,Kouri G.Dengue:an update[J].Lancet Infect Dis,2002,2(1):33-42.
• [4]Stasi R,Provan D.Management of immune thrombocytopenic purpura in adults[J].Mayo Clin Proc,2004,79(4):504-522.
• [5]Shashidhara KC,Murthy KA,Gowdappa HB,et al.Effect of high dose of steroid on plateletcount in acute stage of dengue Fever with thrombocytopenia[J].J Clin Diagn Res,2013,7(7):1397-1400.
• [6]Dimaano EM,Saito M,Honda S,et al.Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection[J].Am J Trop Med Hyg,2007,77(6):1135-1138.
• [7]Sridharan A,Chen Q,Tang KF,et al.Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice[J].J Virol,2013,87(21):11648-11658.